| Primary |
| Breast Cancer |
28.6% |
| Non-small Cell Lung Cancer |
14.6% |
| Premedication |
12.2% |
| Ovarian Cancer |
9.2% |
| Lung Neoplasm Malignant |
8.5% |
| Breast Cancer Metastatic |
4.7% |
| Gastric Cancer |
3.7% |
| Uterine Cancer |
3.6% |
| Lung Adenocarcinoma |
2.3% |
| Neoplasm Malignant |
1.9% |
| Germ Cell Cancer |
1.6% |
| Lung Squamous Cell Carcinoma Stage Unspecified |
1.5% |
| Pain |
1.4% |
| Cervix Carcinoma |
1.3% |
| Hypertension |
1.3% |
| Ovarian Epithelial Cancer |
0.9% |
| Prophylaxis |
0.8% |
| Prostate Cancer |
0.7% |
| Insomnia |
0.6% |
| Oesophageal Carcinoma |
0.6% |
|
| Interstitial Lung Disease |
11.2% |
| Vomiting |
9.9% |
| White Blood Cell Count Decreased |
8.0% |
| Neuropathy Peripheral |
7.1% |
| Pyrexia |
6.6% |
| Malignant Neoplasm Progression |
5.9% |
| Rash |
5.5% |
| Hypersensitivity |
5.0% |
| Renal Failure Acute |
4.7% |
| Death |
4.2% |
| Pulmonary Embolism |
3.9% |
| Thrombocytopenia |
3.7% |
| Extravasation |
3.2% |
| Neuropathy |
3.2% |
| Pneumonitis |
3.1% |
| Acute Myeloid Leukaemia |
3.0% |
| Infusion Related Reaction |
3.0% |
| Shock |
3.0% |
| Dyspnoea |
2.9% |
| Pneumonia |
2.9% |
|
| Secondary |
| Non-small Cell Lung Cancer |
18.5% |
| Breast Cancer |
17.4% |
| Drug Use For Unknown Indication |
11.5% |
| Product Used For Unknown Indication |
9.5% |
| Breast Cancer Metastatic |
7.4% |
| Ovarian Cancer |
4.4% |
| Oesophageal Carcinoma |
3.6% |
| Oesophageal Adenocarcinoma |
3.5% |
| Lung Neoplasm Malignant |
3.4% |
| Hypertension |
3.3% |
| Premedication |
2.7% |
| Pain |
2.2% |
| Prophylaxis |
2.1% |
| Prophylaxis Of Nausea And Vomiting |
1.9% |
| Head And Neck Cancer |
1.8% |
| Nausea |
1.8% |
| Cancer Pain |
1.5% |
| Non-small Cell Lung Cancer Metastatic |
1.3% |
| Insomnia |
1.2% |
| Oesophageal Squamous Cell Carcinoma |
1.0% |
|
| Vomiting |
16.0% |
| White Blood Cell Count Decreased |
14.8% |
| Neutropenia |
8.4% |
| Pyrexia |
7.4% |
| Neutrophil Count Decreased |
5.9% |
| Pneumonia |
4.7% |
| Thrombocytopenia |
4.7% |
| Weight Decreased |
4.1% |
| Pulmonary Embolism |
4.1% |
| Febrile Neutropenia |
3.6% |
| Sepsis |
3.0% |
| Dyspnoea |
2.9% |
| Urinary Tract Infection |
2.9% |
| Dehydration |
2.7% |
| Oesophagitis |
2.7% |
| Tachycardia |
2.7% |
| Nausea |
2.6% |
| Renal Failure |
2.3% |
| Syncope |
2.2% |
| Platelet Count Decreased |
2.2% |
|
| Concomitant |
| Breast Cancer |
22.4% |
| Breast Cancer Metastatic |
13.5% |
| Metastases To Bone |
12.9% |
| Drug Use For Unknown Indication |
9.6% |
| Non-small Cell Lung Cancer |
5.6% |
| Ovarian Cancer |
5.0% |
| Product Used For Unknown Indication |
4.6% |
| Chemotherapy |
4.5% |
| Pain |
3.8% |
| Prophylaxis |
3.0% |
| Premedication |
2.7% |
| Lung Neoplasm Malignant |
2.3% |
| Depression |
1.8% |
| Hypertension |
1.6% |
| Prostate Cancer |
1.5% |
| Neoplasm Malignant |
1.5% |
| Breast Cancer Female |
1.2% |
| Lung Adenocarcinoma |
0.9% |
| Prostate Cancer Metastatic |
0.8% |
| Nausea |
0.8% |
|
| Tooth Extraction |
11.6% |
| Death |
10.9% |
| Vomiting |
10.1% |
| Weight Decreased |
9.3% |
| Disease Progression |
6.2% |
| White Blood Cell Count Decreased |
5.2% |
| Toothache |
5.1% |
| Weight Increased |
4.5% |
| Wound Dehiscence |
4.5% |
| Osteonecrosis |
3.9% |
| Osteonecrosis Of Jaw |
3.9% |
| Pyrexia |
3.4% |
| Wound Treatment |
3.2% |
| Rash |
3.0% |
| Interstitial Lung Disease |
2.9% |
| Thrombocytopenia |
2.5% |
| Wound |
2.5% |
| Wound Debridement |
2.5% |
| Dyspnoea |
2.4% |
| Pain In Extremity |
2.2% |
|
| Interacting |
| Chemotherapy |
20.0% |
| Drug Use For Unknown Indication |
17.5% |
| Malignant Hydatidiform Mole |
12.5% |
| General Anaesthesia |
11.3% |
| Breast Cancer |
6.3% |
| Breast Cancer Metastatic |
5.0% |
| Ovarian Cancer |
5.0% |
| Cancer Pain |
3.8% |
| Essential Hypertension |
2.5% |
| Pulmonary Embolism |
2.5% |
| Venous Thrombosis |
2.5% |
| Acne |
1.3% |
| Anaemia |
1.3% |
| Anxiety |
1.3% |
| Bladder Transitional Cell Carcinoma |
1.3% |
| Constipation |
1.3% |
| Decreased Appetite |
1.3% |
| Hypertension |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
| Tooth Infection |
1.3% |
|
| Unevaluable Event |
20.0% |
| Prothrombin Time Prolonged |
13.3% |
| Reversible Posterior Leukoencephalopathy Syndrome |
13.3% |
| Drug Interaction |
6.7% |
| Ileus |
6.7% |
| International Normalised Ratio Increased |
6.7% |
| Tachycardia |
6.7% |
| Tendonitis |
6.7% |
| Vaginal Haemorrhage |
6.7% |
| Visual Disturbance |
6.7% |
| White Blood Cell Count Decreased |
6.7% |
|
